Morphinan compounds
AssigneeConcert Pharmaceuticals, Inc.
InventorsPhilip B. Graham, I. Robert Silverman
Life of this patent
Estimating the term…
Abstract
This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.
Claims19
1-27. (canceled)
A method of treating a subject suffering from or susceptible to intractable coughing, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is —(C1-C4)alkyl, wherein R1 is optionally substituted with one or more deuterium atoms;
- and
- R2 is selected from CH3, CH2D, CHD2, and CD3;
- provided that at least one deuterium atom is present at either R1 or R2;
- wherein any atom not designated as deuterium is present at its natural isotopic abundance;
- and
- wherein the amount of the compound administered is in the range from 4.0 mg to 350 mg.
A compound selected from:
- wherein the (C1-C4 alkyl) is deuterated.
A method of treating a subject suffering from or susceptible to a disease or condition selected from neurological disorders and neurodegenerative diseases, diabetic neuropathy, neuropathic pain, epileptic seizures, and methotrexate neurotoxicity, comprising the step of administering to the subject in need thereof a therapeutically effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is —(C1-C4)alkyl, wherein R1 is optionally substituted with one or more deuterium atoms;
- and
- R2 is selected from CH3, CH2D, CHD2, and CD3;
- provided that at least one deuterium atom is present at either R1 or R2;
- wherein any atom not designated as deuterium is present at its natural isotopic abundance;
- and
- wherein the amount of the compound administered is in the range from 0.4 mg to 400 mg.
Dependencies are inferred from the claim text.